Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,458 total articles
Micron has delivered blowout results and locked in multi-year customer commitments while trading at a reasonable earnings multiple. Pair traders should close the MU/ SK hynix hedge and keep a directional long in Micron — it offers a higher-quality earnings floor, strong cash generation and balance sheet strength. Trade plan below: enter $805, stop …
Bloom Energy (BE) sits at the intersection of two powerful trends: massive AI infrastructure buildouts and a stressed grid that struggles with interconnection times. Management now guides Q4 revenue to $1.35-$1.55 billion and is ramping capacity toward 5+ GW annually. The stock is volatile and richly valued, but the near-term revenue acceleration a…
We upgrade Inovio (INO) to Buy after the FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis (RRP). The approval creates an immediate commercial pathway, a chance to monetize a late-stage asset and re-rate the stock. INO trades at a $173M market cap with cash on the balance sheet and strong short interest that could…
SpaceX shares have been hit hard by the midterm-driven rotation and a broader AI backlash. That pullback materially widens the risk-reward for patient, tactical longs. We lay out an actionable buy with entry, stop and target and explain the fundamental and catalyst-driven case for staying long.
Nano Labs (NA) is a Hangzhou-based fabless chip and distributed compute play that has pivoted toward AI and Web3 convergence. Market cap sits near $33M, the stock is near its 52-week low and technically oversold, and the company holds a strategic reserve of 70,000 BNB. This trade idea is a speculative long: entry $1.51, stop $1.20, primary target $…
Duolingo's latest quarter showed a clear rebound in core engagement and subscription revenue. With DAUs at 64.9M and Q3 revenue of $309.01M beating estimates, the setup favors a mid-term swing long. Valuation still demands execution, but improving unit economics and attractive free cash flow make this a higher-conviction trade than the selloff earl…
BioMarin (BMRN) delivered an upside EPS surprise and generates healthy free cash flow while still trading well below its 52-week high. With the market focused on several upcoming FDA decisions, a defined long with a $50 stop and a $66 target offers a favorable risk-reward over a swing horizon.
Constellation Energy ($CEG) has pulled back to the low $240s ahead of Q3 results on 11/09/2026. The stock now trades near its 30-day VWAP and below most short-term moving averages, offering a tactical long into earnings and a structured swing toward $295 if results and guidance reinforce the data-center narrative. I lay out a concrete entry, stop a…
Sandisk has seen a brutal price reset from its 2026 highs, but the business metrics - double-digit margins, massive free cash flow and multi-hundred percent revenue growth in the most recent quarter - argue the downside is limited. This trade idea outlines a concrete entry at $1080.00, a stop at $980.00 and a mid-term target of $1600.00 (45 trading…
Floor & Decor (FND) looks buyable around current levels. The retailer reported an EPS beat in Q3 but soft comps and a revenue miss have left the stock unjustly punished. With a clean balance sheet, $342.5M of trailing free cash flow, and an EV/EBITDA of ~8.7, the setup favors a mid-term bounce if mortgage rates stabilize and renovation activity rec…
AI training and inference rollouts are gobbling NAND capacity. That dynamic—combined with Sandisk's astonishing recent revenue run-rate and an 8-for-1 split—sets the stage for a supply shock that could lift pricing and margins across the storage complex. Western Digital (WDC) looks attractively cheap on a pullback, with a strong FCF profile, low le…
Neurocrine reported strong Q3 results and raised Ingrezza guidance; with Crenessity and Vykat XR scaling rapidly and meaningful free cash flow, the stock looks like a compelling long for a 180 trading day horizon. We'll lay out the trade plan, valuation context, catalysts and risks.
ASM International is the dominant supplier of atomic layer deposition (ALD) platforms critical to advanced logic and memory nodes. As foundries and IDMs prepare for 1.4nm production, incremental tool intensity and replacement cycles should support multi-quarter revenue growth. This trade idea outlines a long entry with a clear stop and target, a ca…
AXT reported blowout Q3 results on 10/30/2026 — $73.41M revenue, $0.41 non-GAAP EPS and record InP sales of $54.3M — and guided to even higher margins in Q4. That fundamental strength is real, but the stock already prices a sustained AI-powered re-rating: market cap ~$3.32B, price-to-sales north of 26x and stretched free cash flow. For traders, thi…
Neurocrine (NBIX) reported stronger-than-expected Q3 results on 11/03/2026 and raised Ingrezza sales guidance, driving a rally. The business is producing strong cash flow, and newer franchises are scaling rapidly—arguments that support a tactical long trade on a measured pullback. Technicals are hot, so the plan favors buying a near-term dip with a…
StoneX (SNEX) has retraced sharply from its 52-week high, leaving a lower-risk entry for traders who respect the firm's cyclical exposures. With a market cap near $6.8B, P/E ~13.3, EV/EBITDA ~9.5 and strong free cash flow, the risk/reward favors a measured long over a mid-term horizon. Plan for a disciplined stop and size for volatility.
Eli Lilly is trading near its 52-week high after a blockbuster quarter: Q3 revenue of $24.4B (up 39%) and raised guidance. The company’s scale, cash generation ($19.66B FCF) and premium valuation (market cap ~$1.33T; P/E ~46) argue for a measured long. This trade idea captures upside from continued GLP-1 adoption, pipeline progress and what may be …
Alphabet’s core Search and Cloud franchises are fundamentally resilient, the stock is technically oversold, and valuation metrics leave room for a meaningful rebound. This trade idea recommends a mid-term buy of GOOG at current levels with a clear stop and target. By contrast, Amazon’s capital intensity and cash dynamics make it a less compelling t…
Inspire (INSP) reported a modest Q3 beat on 11/02/2026 and the core business weathered a worst-case coding and reimbursement shock without structural damage. The stock trades at $61.90 with a market cap near $1.79B and a P/E of ~17.8. This trade idea lays out a long swing trade: entry $61.90, stop $52.00, target $87.00, horizon 45 trading days. Key…
MaxLinear's optical data center business is growing at a blistering pace and is starting to justify a premium multiple. Q3 showed a 72% revenue jump and infrastructure (AI optical) up 210% year-over-year. The stock has pulled back from its highs; this trade idea uses a disciplined entry, stop and target to ride the next leg of the AI optics cycle o…
HPE offers a cleaner risk-reward than Dell right now: cheaper relative valuation, strong free cash flow, a positive earnings surprise setup, and an edge-to-cloud portfolio that can monetize AI and hybrid-cloud demand without the same capital intensity and backlog risk Dell carries. I lay out a mid-term trade plan, catalysts, and the risks that coul…
<p>Tiptree is trading at roughly 70% of book value with an enterprise value that is negative, implying the company is carrying more cash than the market values it for. That alone makes the downside asymmetric, but upside requires clarity on how management will deploy or return the Fortegra proceeds. For patient investors, this is a hold; for trader…
Eli Lilly's revenue momentum from GLP-1 drugs is real - Q3 revenue rose 39% to $24.4B - but realized prices have declined roughly 15%, compressing margin upside and leaving the stock richly valued. We recommend a measured mid-term long (45 trading days) on a pullback to $1,390 with a stop at $1,320 and a $1,550 target. The trade leans on continued …
MSGS is a play on sports fandom turning into near-term revenue and sentiment upside. With the Rangers' season underway and predictable cadence of ticketing, local media, and sponsorship milestones ahead, this trade aims to capture a mid-term re-rating. Entry at $32.00 with a $44.00 target and $24.00 stop balances upside from event-driven catalysts …
Celestica is growing into AI data-center demand: reported quarterlies show revenue accelerating ~80%-100% in core connectivity and cloud segments and management has pushed revenue targets meaningfully higher. The shares have declined roughly 30% in recent weeks despite the growth; this setup offers a defined long trade with clear entry, stop and ta…
